Snap-8
Argireline-type topical cosmetic peptide; evidence is limited and cosmetic, not from injectable aesthetic medicine.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
Snap-8 is an acetylated octapeptide that, in theory, interferes with the SNARE complex and reduces acetylcholine release in models — the same narrative as Argireline. In practice, it is an active ingredient in creams, with penetration to the facial neuromuscular junction not demonstrated like that of botulinum toxin. If Peptira lists a research vial, the classic cosmetic use remains topical; do not assume injectable equivalence.
Studied for
How it works
Competition/modulation of SNARE assembly in vitro → less ACh exocytosis in cell assays. Topical clinical translation: uncertain and likely modest.
What the research says
Cosmetic literature and reviews of biomimetic peptides in dermatology. No robust, independent, toxin-type pharmacological RCTs. There are no solid registered clinical trials for injectable Snap-8.
Evidence level
C–D — small/manufacturer-linked cosmetic studies; not a drug
What's most reported
- Cosmetic reduction of wrinkle depth in small studies
- Good topical tolerance, common in formulas
Common side effects
Topical: low irritation typical of cosmetics. Injectable research: not characterized — do not recommend.
Combines / does not combine
Does not replace medical botulinum toxin. Avoid injecting cosmetics.
Frequently asked questions
No.
The classic studied/commercial use is topical. Injecting research Snap-8 is not supported.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidelines. Research products are not approved drugs unless otherwise indicated.